Glytec and Roche Diagnostics USA last month announced a digital health collaboration that combines Roche’s expertise in medical devices and IT solutions with Glytec’s FDA-cleared insulin dosing decision support software, Glucommander™, to address the pervasive challenges with inpatient blood sugar management at the hospital bedside. Glucommander will be the first software application available to run on Roche’s smart device next-generation hospital blood glucose system, cobas® pulse, which is designed with the intention of improving patient safety and care by empowering point-of-care clinicians to collect and take immediate action on glycemic management data.
Glucommander has been proven to reduce severe low blood sugar by 99.8%, 30-day readmissions by 36% – 68%, and length of stay by up to 3.2 days. The safety and efficacy of Glucommander have been validated in hundreds of research studies.
This combination of hardware and software is designed to help nurses and physicians close the gap between getting data and taking action. Clinicians’ time is their most limited resource: The objectives of the partnership are to combine the immediacy of a bedside blood glucose test with Glytec’s insulin decision support on a single, handheld device with the intention of streamlining workflows and saving time. The integrated device and applications are designed to improve patient safety and outcomes by empowering point-of-care clinicians to collect and take immediate action on glycemic management data.
“From the temporary allowance of CGM usage inside health systems to the recent CMS eCQMs around severe hypoglycemia and severe hyperglycemia, there has been a groundswell of focus on inpatient glycemic management across the healthcare industry,” says Jordan Messler, MD, SFHM, FACP, chief medical officer at Glytec. “Our partnership with Roche is exciting because it showcases two industry leaders working closely together to embrace this heightened focus and address the significant challenges hospitals face with inpatient blood sugar management.”
“Combining Glytec’s proven insulin dosing support software, Glucommander, with Roche’s next generation handheld blood glucose system allows us to design an end-to-end solution that will empower clinicians to take immediate action on real-time glycemic data, saving time and streamlining workflows. Glucommander’s approach to personalized insulin dosing has been shown to improve patient safety and reduce time to target blood glucose range — this collaboration will add even more benefits that improve patient outcomes,” Messler adds.
This article originally appeared in Endocrine News.
MAR-0000949 Rev 1.0